Exploring the Potential for JAK1 Selectivity in Autoimmune Dermatological Conditions
Time: 1:15 pm
day: Day One
Details:
- Overcoming pre-clinical hurdles in dermatology to enable topical JAK inhibitor development
- Considering route of delivery and the implications on safety and efficacy
- Preparing a JAK inhibitor pipeline for transition from pre-clinic to phase 1 trials
